Literature DB >> 19050874

Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Frederik A Verburg, Markus Dietlein, Michael Lassmann, Markus Luster, Christoph Reiners.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19050874     DOI： 10.1007/s00259-008-0997-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  41 in total

1.  Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.

Authors:  Richard T Kloos; Vani Duvuuri; Sissy M Jhiang; Kenneth V Cahill; Jill A Foster; John A Burns
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

2.  [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].

Authors:  M Dietlein; J Dressler; W Eschner; F Grünwald; M Lassmann; B Leisner; M Luster; C Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

Review 3.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

4.  Thyroid cancer and multiple primary tumors in the SEER cancer registries.

Authors:  Cécile M Ronckers; Peter McCarron; Elaine Ron
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

5.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

6.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

Review 8.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

9.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.

Authors:  S I Sherman; E T Tielens; S Sostre; M D Wharam; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].

Authors:  M Dietlein; J Dressler; W Eschner; F Grünwald; M Lassmann; B Leisner; M Luster; E Moser; Chr Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379
View more
  10 in total

1.  I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?

Authors:  Frederik A Verburg; Luca Giovanella; Ioannis Iakovou; Mark W Konijnenberg; Werner Langsteger; Michael Lassmann; Jasna Mihailovic; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-08       Impact factor: 9.236

2.  Analysis of tissue surrounding thyroid nodules by ultrasound digital images.

Authors:  Pierpaolo Trimboli; Fabiano Bini; Massimiliano Andrioli; Luca Giovanella; Maria Francesca Thorel; Luca Ceriani; Stefano Valabrega; Andrea Lenzi; Francesco Maria Drudi; Franco Marinozzi; Francesco Romanelli
Journal:  Endocrine       Date:  2014-07-06       Impact factor: 3.633

Review 3.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

4.  Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.

Authors:  Frederik A Verburg; Martha Hoffmann; Ioannis Iakovou; Mark W Konijnenberg; Jasna Mihailovic; Pablo Minguez Gabina; Petra Petranović Ovčariček; Cristoph Reiners; Alexis Vrachimis; Slimane Zerdoud; Luca Giovanella; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03       Impact factor: 9.236

Review 5.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

6.  Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.

Authors:  Klaus Schomäcker; Ferdinand Sudbrock; Thomas Fischer; Markus Dietlein; Carsten Kobe; Mark Gaidouk; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-17       Impact factor: 9.236

7.  Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.

Authors:  Daniela Schmidt; Rainer Linke; Michael Uder; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

8.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236

9.  Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Authors:  Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-01       Impact factor: 9.236

10.  The Evaluation of Microcarcinoma in Differentiated Thyroid Cancers According to Old and New TNM Classification.

Authors:  Zekiye Hasbek; Bülent Turgut; Taner Erselcan; Ayhan Koyuncu; Mehmet Fatih Börksüz; Nergiz Hacer Turgut; Fadime Yumuk
Journal:  Mol Imaging Radionucl Ther       Date:  2011-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.